Cisplatin

News Cisplatin

• Cisplatin-resistant cancer cells sensitive to experimental anticancer drugs, PARP inhibitors

  Poly (ADP-ribose) polymerase inhibitors may be a novel treatment strategy for patients with cancer that has become resistant to the commonly used chemotherapy drug cisplatin, according to data from a preclinical study published in Cancer Research. "Cisplatin is one of the most widely used convention more

• Idera Pharmaceuticals Achieves Clinical Milestone Under Its Collaboration with Merck KGaA for Cancer Treatment

  Idera Pharmaceuticals, Inc. announced that it has achieved a milestone under its worldwide licensing and collaboration agreement with Merck KGaA. The milestone was achieved upon Merck KGaA’s initiation of a Phase 1b clinical trial of IMO-2055 (EMD 1201081), an agonist of Toll-like Receptor 9 (TLR9), more

• Significant advance announced in treatment of cervical cancer

  A medical researcher at the University of Leicester has made a significant advance in the treatment of cervical cancer. Dr Paul Symonds from the Department of Cancer Studies and Molecular Medicine has demonstrated that the use of a particular drug in collaboration with radiotherapy gives significant more

Publications Cisplatin

• Genetic disruption of Abl nuclear import reduces renal apoptosis in a mouse model of cisplatin-induced nephrotoxicity

  Genetic disruption of Abl nuclear import reduces renal apoptosis in a mouse model of cisplatin-induced nephrotoxicity Cell Death and Differentiation advance online publication, May 10 2013. doi:10.1038/cdd.2013.42 Authors: P Sridevi, M K Nhiayi & J Y J Wang more

• SERPINB2 down‐regulation contributes to chemoresistance in head and neck cancer

  Abstract Resistance to cisplatin‐based chemotherapy is responsible for the majority of deaths from head and neck squamous cell carcinoma (HNSCC). In this study, using genome‐wide gene expression analysis to investigate potential molecular mediators of HNSCC chemoresistance, we identified SERPIN more

• Peptide YY3–36 and 5-Hydroxytryptamine Mediate Emesis Induction by Trichothecene Deoxynivalenol (Vomitoxin)

  Deoxynivalenol (DON, vomitoxin), a trichothecene mycotoxin produced by Fusarium sp. that frequently occurs in cereal grains, has been associated with human and animal food poisoning. Although a common hallmark of DON-induced toxicity is the rapid onset of emesis, the mechanisms for this adverse eff more

Market studies Cisplatin

• Melanoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019

  Introduction GlobalData, the industry analysis specialist, has released its new report, “Melanoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global melanoma therapeutics market. The report identifies the key more

• Brentuximab Vedotin – First Treatment Option for Relapsed Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (Subset of Non-Hodgkin Lymphoma)

  Introduction The group of cancers that originate in the lymphatic system are known as lymphoma. Lymphoma is broadly classified into two types: Hodgkin lymphoma and non-Hodgkin lymphoma. In 2010, more than 16,887 new cases of Hodgkin lymphoma and 139,507 new cases of non-Hodgkin lymphoma were diagno more

• Ivy Medical Chemicals PLC (IVMP) - Financial and Strategic SWOT Analysis Review

  Ivy Medical Chemicals PLC (Ivy Medical) is engaged in the development and marketing of medical products to oncology markets. The company's flagship product, CV 247 was approved in Hungary for cancer treatment. Ivy Medical also sells CV 247 to the veterinary market in the UK. CV247 is a combination p more

Websites Cisplatin